WHAT IS CLAIMED IS:

1. A dosage form for extended release of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (BMS-986165), the dosage form comprising: (i) an internal phase comprising a spray-dried dispersion of BMS-986165 in a polymer matrix; and (ii) an external phase comprising a release-controlling polymer.

2. The dosage form according to claim 1, wherein the release-controlling polymer is selected from methylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, carboxymethylcellulose, sodium carboxymethylcellulose, ethyl cellulose, sodium alginate, chitosan, gelatin, tragacanth, xanthan, and mixtures thereof.

3. A dosage form for extended release of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (BMS-986165), the dosage form comprising: (i) an internal phase comprising a dispersion of amorphous BMS-986165 in a polymer matrix; (ii) an external phase comprising a release-controlling polymer; and (iii) a crystallization inhibitor, which is in the external phase.

4. The dosage form according to claim 3, wherein the release-controlling polymer is selected from methylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, carboxymethylcellulose, sodium carboxymethylcellulose, ethyl cellulose, sodium alginate, chitosan, gelatin, tragacanth, xanthan, and mixtures thereof.

5. The dosage form according to claim 3, wherein the crystallization inhibitor is selected from polyvinyl pyrrolidone (PVP), PVP vinyl acetate, hydroxypropyl methylcellulose, methylcellulose, cellulose acetate phthalate, hydroxypropyl cellulose, polymethacrylate-based copolymers, polyvinylcaprolactam-based copolymers, hydroxypropyl methylcellulose acetate succinate, and mixtures thereof.

6. The dosage form according to claim 3, wherein the polymer matrix is hydroxypropyl methylcellulose acetate succinate (HPMCAS), and the release-controlling polymer is hydroxypropyl methylcellulose (HPMC).

7. The dosage form according to claim 3, wherein the crystallization inhibitor is hydroxypropyl methylcellulose acetate succinate (HPMCAS).

8. The dosage form according to claim 3, which is an oral dosage form.

9. Use of the dosage form according to any one of claims 1–7 in the manufacture of a medicament for treating an auto-immune disease or auto-inflammatory disease in a subject.

10. Use of the oral dosage form according to claim 8 in the manufacture of a medicament for treating an auto-immune disease or auto-inflammatory disease in a subject.

11. The use according to claim 9, wherein the subject is a human subject.

12. The use according to claim 10, wherein the subject is a human subject.

13. Use of the dosage form according to any one of claims 1–8 in the manufacture of a medicament for treating an inflammatory bowel disease in a subject, wherein the medicament is to be administered once daily to the subject.

14. The use according to claim 13, wherein the dosage form is a tablet containing 12 to 36 mg of BMS-986165.

15. The use according to claim 13, wherein the dosage form is a tablet containing 15 mg of BMS-986165.

16. The use of claim 13, wherein the inflammatory bowel disease is ulcerative colitis.

17. The use of claim 13, wherein the inflammatory bowel disease is Crohn’s disease.